Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMB Study: Truvada or Emtricitabine monotherapy versus HAART interruption in HIV-infected patients with TAMs and M184V
2005-004654-28Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of emtricitabine + tenofovir disoproxil, emtricitabine in human immunodeficiency virus infection (HIV), Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Started Jun 2006; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxilemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-004654-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004654-28.